Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210075 | 0.82 | NPC1 (0.50) | CHRNB2CHRNA4MAPTMEN1KMT2A | |
| SCHEMBL14867787 | 0.82 | CHRNB2 (0.39) | CHRNB2CHRNA4OPRM1OPRD1OPRK1 | |
| SCHEMBL10268122 | 0.82 | CHRNB2 (0.38) | CHRNB2CHRNA4MAPTMEN1KMT2A | |
| SCHEMBL12829020 | 0.82 | OPRD1 (0.43) | OPRM1OPRD1MAPTHTR2CSMN1; SMN2 | |
| SCHEMBL16365106 | 0.82 | PROKR1 (0.45) | OPRM1OPRD1OPRK1MAPTMEN1 | |
| SCHEMBL586754 | 0.81 | NPC1 (0.49) | CHRNB2CHRNA4MAPTMEN1KMT2A | |
| Benzene SCHEMBL28160719 | 0.81 | NPC1 (0.49) | CHRNB2CHRNA4MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL16321640 | 0.81 | PROKR1 (0.44) | OPRM1OPRD1OPRK1MAPTMEN1 | |
| SCHEMBL15281415 | 0.81 | CHRNB2 (0.38) | CHRNB2CHRNA4MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27166094 | 0.81 | OPRD1 (0.43) | OPRM1OPRD1MAPTHTR2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| CN-114401731-A | Compositions and methods for treating human immunodeficiency virus | 奇达拉治疗公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3982993-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-2601174-B1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-1513832-B1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-1513832-B1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8450361-B2 | Substituted indole and azaindole oxoacetyl piperazinamide derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| EP-1751161-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005054247-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | SILEO, LLC | 2005-06-09 | — | — | US | disclosed |
| EP-1513832-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| WO-2004043337-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | CHRNB2 4499/4885CHRNA4 2786/4885OPRM1 348/4885 |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | EIF2AK2, ITPA, MAVS | CHRNB2 4824/4885CHRNA4 4682/4885OPRM1 286/4885 |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | CHRNB2 4499/4885CHRNA4 2786/4885OPRM1 348/4885 |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | FCGR3B, FCGR1A, FCGR2A | CHRNB2 4559/4885CHRNA4 4040/4885OPRM1 200/4885 |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | CD4, CCR5, PAICS | CHRNB2 4084/4885CHRNA4 3517/4885OPRM1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.